Back

Can gene editing address unmet need in dyslipidaemia?

30 August 2025 (09:09 - 09:27)
Organised by: Logo
Congress Presentation Part of: What’s new in lipids? Lipids ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Amit Khera

Verve Therapeutics, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
What’s new in LDL lowering?
Professor L. Tokgozoglu (Ankara, TR)
Slides Video
Presentation thumbnail
Do triglycerides matter?
Professor B. Nordestgaard (Copenhagen, DK)
Slides Video
Presentation thumbnail
Lp(a): small molecule, big trouble
Professor F. Kronenberg (Innsbruck, AT)
Slides Video
Presentation thumbnail
What’s new in lipids? - discussion
Video

Access the full session

Session thumbnail
What’s new in lipids?
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 09:09 CET
You may be interested in
thumbnail
Congress Session
What’s new in lipids?
thumbnail
Congress Presentation
Monoclonal antibodies, gene silencing, and gene editing (CRISPR) therapies for the treatment of hyperlipidaemia
thumbnail
Congress Presentation
An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources